These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 10866357)
1. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity. Teplán I Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357 [TBL] [Abstract][Full Text] [Related]
2. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines. Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040 [TBL] [Abstract][Full Text] [Related]
3. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308 [TBL] [Abstract][Full Text] [Related]
4. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. Tejeda M; Gaal D; Barna K; Csuka O; Kéri G Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models. Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564 [TBL] [Abstract][Full Text] [Related]
6. In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity. Vincze B; Pályi I; Gaál D; Pató J; Móra M; Mezõ I; Teplán I; Seprõdi J Cancer Detect Prev; 1996; 20(2):153-9. PubMed ID: 8706041 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Kéri G; Mezô I; Vadász Z; Horváth A; Idei M; Vántus T; Balogh A; Bökönyi G; Bajor T; Teplán I Pept Res; 1993; 6(5):281-8. PubMed ID: 7903057 [TBL] [Abstract][Full Text] [Related]
8. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships. Mezö I; Lovas S; Pályi I; Vincze B; Kálnay A; Turi G; Vadász Z; Seprödi J; Idei M; Tóth G; Gulyás E; Otvös F; Mák M; Horváth JE; Teplán I; Murphy RF J Med Chem; 1997 Oct; 40(21):3353-8. PubMed ID: 9341910 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of GnRH agonist in epithelial ovarian cancer. Kim JH; Park DC; Kim JW; Choi YK; Lew YO; Kim DH; Jung JK; Lim YA; Namkoong SE Gynecol Oncol; 1999 Aug; 74(2):170-80. PubMed ID: 10419728 [TBL] [Abstract][Full Text] [Related]
10. Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells? Herédi-Szabó K; Murphy RF; Lovas S J Pept Sci; 2006 Nov; 12(11):714-20. PubMed ID: 16967433 [TBL] [Abstract][Full Text] [Related]
11. Novel antitumor peptide hormones and their effect on signal transduction. Kéri G; Balogh A; Horváth A; Mezö I; Vadász Z; Bökönyi G; Bajor T; Vántus T; Teplán I; Horváth J J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):105-10. PubMed ID: 1356011 [TBL] [Abstract][Full Text] [Related]
12. Effects of GnRH analogs on six ovarian cancer cell lines in culture. Connor JP; Buller RE; Conn PM Gynecol Oncol; 1994 Jul; 54(1):80-6. PubMed ID: 8020844 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity. Mezô I; Seprôdi J; Vincze B; Pályi I; Kéri G; Vadász Z; Tóth G; Kovács M; Koppán M; Horváth JE; Kálnay A; Teplán I Biomed Pept Proteins Nucleic Acids; 1996; 2(2):33-40. PubMed ID: 9346824 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P; Cameron R; Wang J; Vallis KA; Reilly RM J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194 [TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate. Mezö G; Mezö I; Pimm MV; Kajtár J; Seprödi J; Teplán I; Kovács M; Vincze B; Pályi I; Idei M; Szekerke M; Hudecz F Bioconjug Chem; 1996; 7(6):642-50. PubMed ID: 8950483 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470 [TBL] [Abstract][Full Text] [Related]
18. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion. Murphy WA; Taylor JE; Moreau JP; Coy DH Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697 [TBL] [Abstract][Full Text] [Related]
19. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Weckbecker G; Raulf F; Bodmer D; Bruns C Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482 [TBL] [Abstract][Full Text] [Related]
20. Direct inhibiting effects of [D-Trp6]gonadotropin-releasing hormone on the estrogen-sensitive progression of polyoma virus-induced mammary tumors in athymic mice. Néri C; Blangy D; Schatz B; Drieu K; Berebbi M; Martin PM Cancer Res; 1990 Sep; 50(18):5892-7. PubMed ID: 2168284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]